EA199800208A1 - Усовершенствованные способы изготовления нековалентно комплексированных и поливалентных вакцин протеосомной подгруппы - Google Patents

Усовершенствованные способы изготовления нековалентно комплексированных и поливалентных вакцин протеосомной подгруппы

Info

Publication number
EA199800208A1
EA199800208A1 EA199800208A EA199800208A EA199800208A1 EA 199800208 A1 EA199800208 A1 EA 199800208A1 EA 199800208 A EA199800208 A EA 199800208A EA 199800208 A EA199800208 A EA 199800208A EA 199800208 A1 EA199800208 A1 EA 199800208A1
Authority
EA
Eurasian Patent Office
Prior art keywords
ultrafiltration
production
amphiphilic
diafiltration
proteasome
Prior art date
Application number
EA199800208A
Other languages
English (en)
Inventor
Джордж Х. Лоувелл
Венделл Д. Золлингер
Джеймс Ф. Вудс
Original Assignee
Юнайтед Стэйтс Арми Медикал Ресерч Материэл Комманд (Юсамрмк)
Джордж Х. Лоувелл
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21707938&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA199800208(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Юнайтед Стэйтс Арми Медикал Ресерч Материэл Комманд (Юсамрмк), Джордж Х. Лоувелл filed Critical Юнайтед Стэйтс Арми Медикал Ресерч Материэл Комманд (Юсамрмк)
Publication of EA199800208A1 publication Critical patent/EA199800208A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
    • A23J1/00—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites
    • A23J1/008—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites from microorganisms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1275—Lipoproteins; Chylomicrons; Artificial HDL, LDL, VLDL, protein-free species thereof; Precursors thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/25—Shigella (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Dispersion Chemistry (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Способ изготовления поливалентных вакцин с протеосом-амфифильной детерминантой, пригодных для применения парентерально или через слизистую оболочку, с использованием диафильтрационной или ультрафильтрационной технологии. Амфифильные детерминанты включают липополисахариды грамотрицательных бактерий, например S.flexneri, P.shigelloides и S.sonnei. Протеосомы получены из менингококков группы В типа 2b. Активные вакцинные комплексы (нековалентные комплексы) с протеосом-амфифильной детерминантой изготовлены с использованием диафильтрации или ультрафильтрации для удаления детергента. Применение диа- или ультрафильтрации сокращает время переработки и уменьшает возможность загрязнения, а также позволяет осуществлять процесс при комнатной температуре и эффективно повышать масштабы производства. К тому же способ дает возможность надежно и непрерывно контролировать диализат, что повышает эффективность процесса в целом. Время диализа при изготовлении вакцинной серии сокращено с 7-10 суток до 72 ч и менее, а на практике - менее чем до 48 или 24 ч. Использование способа позволяет оптимизировать содержание каждого антигенного компонента в препаратах поливалентных вакцин.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA199800208A 1995-09-18 1996-09-18 Усовершенствованные способы изготовления нековалентно комплексированных и поливалентных вакцин протеосомной подгруппы EA199800208A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US385995P 1995-09-18 1995-09-18
PCT/US1996/015002 WO1997010844A1 (en) 1995-09-18 1996-09-18 Improved methods for the production of non-covalently complexed and multivalent proteosome sub-unit vaccines

Publications (1)

Publication Number Publication Date
EA199800208A1 true EA199800208A1 (ru) 1998-10-29

Family

ID=21707938

Family Applications (1)

Application Number Title Priority Date Filing Date
EA199800208A EA199800208A1 (ru) 1995-09-18 1996-09-18 Усовершенствованные способы изготовления нековалентно комплексированных и поливалентных вакцин протеосомной подгруппы

Country Status (20)

Country Link
US (1) US6476201B1 (ru)
EP (1) EP0854729B2 (ru)
JP (2) JP4033489B2 (ru)
KR (1) KR19990045763A (ru)
CN (1) CN1211192A (ru)
AT (1) ATE261313T1 (ru)
BR (1) BR9610484A (ru)
CA (1) CA2232410C (ru)
CZ (1) CZ298460B6 (ru)
DE (1) DE69631835T3 (ru)
DK (1) DK0854729T3 (ru)
EA (1) EA199800208A1 (ru)
ES (1) ES2217325T5 (ru)
HU (1) HUP9901577A3 (ru)
IL (1) IL123720A (ru)
MX (1) MX9802128A (ru)
NO (1) NO320074B1 (ru)
PL (1) PL325604A1 (ru)
PT (1) PT854729E (ru)
WO (1) WO1997010844A1 (ru)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5961970A (en) 1993-10-29 1999-10-05 Pharmos Corporation Submicron emulsions as vaccine adjuvants
BR9910749A (pt) * 1998-05-29 2001-02-13 Chiron Corp Composições e vacinas imunogênicas combinadas para meningites b e c e método de induzir uma resposta imune por administração da mesma
RU2245366C2 (ru) 1999-04-30 2005-01-27 Чирон С.Р.Л. Антиген neisseria, кодирующая его нуклеиновая кислота, их использование
EP2270174A1 (en) 1999-05-19 2011-01-05 Novartis Vaccines and Diagnostics S.r.l. Combination neisserial compositions
EP1721618A3 (en) * 2000-02-15 2007-01-10 ID Biomedical Corporation of Quebec Proteosome influenza vaccine composition
DE60121136T2 (de) 2000-02-15 2007-06-06 Id Biomedical Corporation Of Quebec, Ville St. Laurent Proteasom-influenzavirus-impfstoffzusammensetzung
PT2270030E (pt) 2000-02-28 2012-07-24 Novartis Vaccines & Diagnostic Expressão heteróloga de proteínas de neisseria
EP1372706B1 (en) * 2001-03-09 2010-12-01 ID Biomedical Corporation of Quebec Proteosome-liposaccharide vaccine adjuvant
KR101239242B1 (ko) * 2002-08-02 2013-03-11 글락소스미스클라인 바이오로지칼즈 에스.에이. 항원 조합물을 포함하는 나이세리아 백신 조성물
WO2004032958A1 (en) 2002-10-11 2004-04-22 Chiron Srl Polypeptide-vaccines for broad protection against hypervirulent meningococcal lineages
US7255867B2 (en) * 2002-11-15 2007-08-14 Id Biomedical Corporation Of Quebec Vaccine
GB0316560D0 (en) * 2003-07-15 2003-08-20 Chiron Srl Vesicle filtration
US7368537B2 (en) * 2003-07-15 2008-05-06 Id Biomedical Corporation Of Quebec Subunit vaccine against respiratory syncytial virus infection
JP2007505836A (ja) * 2003-09-15 2007-03-15 アイディー バイオメディカル コーポレイション オブ ケベック 麻疹サブユニットワクチン
JP4966661B2 (ja) 2003-10-22 2012-07-04 アイディー バイオメディカル コーポレイション オブ ケベック 生得的免疫およびアレルギー性免疫を活性化させるための組成物および方法
CA2571035A1 (en) * 2004-06-25 2006-01-12 Id Biomedical Corporation Of Quebec Compositions and methods for treating neurological disorders
AU2005319716A1 (en) * 2004-06-30 2006-06-29 Id Biomedical Corporation Of Quebec Vaccine compositions for treating coronavirus infection
US7552948B2 (en) 2006-03-29 2009-06-30 Tokai Rubber Industries, Ltd. Quick connector
CN101553246B (zh) * 2006-08-07 2019-05-21 哈佛大学校长及研究员协会 蛋白质基质疫苗及这种疫苗的制备和给药方法
EP2056871B1 (en) * 2006-08-07 2017-11-15 President and Fellows of Harvard College Protein matrix vaccines and methods of making and administering such vaccines
WO2008027861A1 (en) * 2006-08-30 2008-03-06 Ge Healthcare Bio-Sciences Corp. System and method for characterizing membranes and membrane filtration devices
BRPI0913268A2 (pt) * 2008-05-30 2016-03-15 U S A As Represented By The Secretary Of The Army On Behalf Of Walter Reed Army vacina de vesícula de membrana externa nativa multivalente meningocócica, métodos de fabricação e uso da mesma
EP2473188A4 (en) * 2009-09-09 2014-01-01 Matrivax Res & Dev Corp PROTEIN MATRIX VACCINES WITH IMPROVED IMMUNOGENICITY
JP6590916B2 (ja) * 2014-09-24 2019-10-16 ザ ユナイテッド ステイツ オブ アメリカ アズ レプレゼンティッド バイ ザ セクレタリー オブ ザ ネイビーＴｈｅ Ｕｎｉｔｅｄ Ｓｔａｔｅｓ Ｏｆ Ａｍｅｒｉｃａ Ａｓ Ｒｅｐｒｅｓｅｎｔｅｄ Ｂｙ Ｔｈｅ Ｓｅｃｒｅｔａｒｙ Ｏｆ Ｔｈｅ Ｎａｖｙ 毒素原性大腸菌およびジェジュニ菌の組合せの組換えコンストラクト
CA3208643A1 (en) 2021-01-18 2022-07-21 Conserv Bioscience Limited Coronavirus immunogenic compositions, methods and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4707543A (en) * 1985-09-17 1987-11-17 The United States Of America As Represented By The Secretary Of The Army Process for the preparation of detoxified polysaccharide-outer membrane protein complexes, and their use as antibacterial vaccines
RU1522494C (ru) * 1987-06-16 1994-11-15 Научно-производственное объединение "Иммунопрепарат" Способ получения инактивированной вакцины гриппа
RU2023448C1 (ru) * 1987-07-30 1994-11-30 Сентро Насьональ Де Биопрепарадос Способ получения вакцины против различных патогенных серотипов менингита нейссера группы в
US5145702A (en) * 1988-09-19 1992-09-08 Opta Food Ingredients, Inc. Hydrophobic protein microparticles and preparation thereof
EP0449958B9 (en) * 1988-12-19 2003-05-28 American Cyanamid Company Meningococcal class 1 outer-membrane protein vaccine
US5102989A (en) * 1991-03-15 1992-04-07 Merck & Co., Inc. Method of stabilizing recombinant hepatitis B virus surface proteins from recombinant host cells
CA2139517A1 (en) * 1992-07-20 1994-02-03 Paul M. Keller Immunological conjugates of ompc and hiv-specific selected principal neutralization epitopes
US5576016A (en) * 1993-05-18 1996-11-19 Pharmos Corporation Solid fat nanoemulsions as drug delivery vehicles
AU5543294A (en) * 1993-10-29 1995-05-22 Pharmos Corp. Submicron emulsions as vaccine adjuvants
DE60121136T2 (de) * 2000-02-15 2007-06-06 Id Biomedical Corporation Of Quebec, Ville St. Laurent Proteasom-influenzavirus-impfstoffzusammensetzung

Also Published As

Publication number Publication date
IL123720A0 (en) 1998-10-30
PL325604A1 (en) 1998-08-03
MX9802128A (es) 1998-11-29
ATE261313T1 (de) 2004-03-15
HUP9901577A2 (hu) 1999-08-30
CZ81998A3 (cs) 1998-10-14
DE69631835D1 (de) 2004-04-15
ES2217325T3 (es) 2004-11-01
JP4033489B2 (ja) 2008-01-16
CA2232410C (en) 2003-06-17
EP0854729B2 (en) 2008-10-22
HUP9901577A3 (en) 2000-03-28
US20020164357A1 (en) 2002-11-07
DE69631835T2 (de) 2005-02-10
BR9610484A (pt) 2001-09-11
NO320074B1 (no) 2005-10-17
EP0854729A1 (en) 1998-07-29
EP0854729B1 (en) 2004-03-10
US6476201B1 (en) 2002-11-05
PT854729E (pt) 2004-08-31
CN1211192A (zh) 1999-03-17
EP0854729A4 (en) 2000-02-02
JP2004099619A (ja) 2004-04-02
DE69631835T3 (de) 2009-03-05
CA2232410A1 (en) 1997-03-27
DK0854729T3 (da) 2004-07-12
WO1997010844A1 (en) 1997-03-27
NO981189L (no) 1998-05-14
JP2000507913A (ja) 2000-06-27
KR19990045763A (ko) 1999-06-25
NO981189D0 (no) 1998-03-17
IL123720A (en) 2002-02-10
ES2217325T5 (es) 2009-04-01
CZ298460B6 (cs) 2007-10-10

Similar Documents

Publication Publication Date Title
EA199800208A1 (ru) Усовершенствованные способы изготовления нековалентно комплексированных и поливалентных вакцин протеосомной подгруппы
NO913518L (no) Vaksiner for ikke typebestembar haemophilus influenzae.
Verstreate et al. Outer membrane proteins of Brucella abortus: isolation and characterization
FI79024C (fi) Foerfarande foer framstaellning av haemophilus influenzae b-polysackaridexotoxoidkonjugatvaccin.
CA1146862A (en) Multivalent pneumococcal vaccine and preparation thereof
HRP20170845T1 (hr) Hiperbulirajući sojevi bakterije shigella
JP2006520205A5 (ru)
JPH01125328A (ja) 髄膜炎菌ワクチン
SE9003278D0 (sv) Foerfarande respektive anlaeggning foer beredning av en medicinsk loesning, t ex en dialysloesning
EA010057B1 (ru) Инактивированная полиомиелитная вакцина, полученная из штамма сейбина вируса полиомиелита
JP4874339B2 (ja) Ｉｐｖ−ｄｐｔワクチン
PT90310B (pt) Processo para a obtencao de preparacoes de adenilato-ciclase
CH662056A5 (fr) Procede de purification de polyosides de streptococcus pneumoniae et vaccin a base de polyosides ainsi purifies.
EP0082072B1 (fr) Procédé de production d'un vaccin biochimique contre les fièvres à salmonelles
US3769415A (en) Method of preparing a killed vaccine for oral use
EP0090660A3 (en) Neisseria gonorrhoeae vaccine
NO124840B (ru)
JPH03135923A (ja) 百日咳毒素ｂオリゴマーの構成サブユニットを含有する経鼻接種ワクチン
DK0500576T3 (da) Ydre membranprotein P1 og peptider fra Haemophilus inluenzae type b
IT1206250B (it) Stiche umane e relativi prodotti metodo per l'estrazione di antigeni di membrana aventi proprieta' immunogene a partire da cellule neopla-
US6413515B1 (en) Avian, vitelline antibodies directed against HIV antigens
CA1206879A (en) Method of obtaining of interferon and interferon in complex with antibacterial and antitoxic substances
DE68913212D1 (de) Ein reines faktor i-protein und verfahren zur herstellung.
SU1725904A1 (ru) Способ получени бруцеллезной вакцины из штамма 82
JPH0689025B2 (ja) 卵黄からの水溶性タンパク質の回収方法